LCMV GP (61-80)
Based on 1 publication(s) in Google Scholar
LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4+ T-cell response.
For research use only. We do not sell to patients.
- Purity: 99.62%
- CAS No.: 232598-19-5
- Formula: C108H160N24O31
- Molecular Weight:2290.60
-
Storage:
Sealed storage, away from moisture and light, under nitrogen.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) LCMV GP (61-80)
More
Biological Activity
Chemical Information
-
CAS No. 232598-19-5
-
Appearance Solid
-
Molecular Weight 2290.60
-
Formula C108H160N24O31
-
Color White to off-white
-
Sequence
Gly-Leu-Lys-Gly-Pro-Asp-Ile-Tyr-Lys-Gly-Val-Tyr-Gln-Phe-Lys-Ser-Val-Glu-Phe-Asp
-
Sequence Shortening
GLKGPDIYKGVYQFKSVEFD
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture and light, under nitrogen
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Eur J Immunol
A Novel Murine Model of Hemophagocytic Lymphohistiocytosis-Like Inflammation in ZNFX1 Deficiency. [Abstract]2026 Feb;56(2):e70141. PMID: 41636200
Solvent & Solubility
H2O : 0.71 mg/mL (0.31 mM; Need ultrasonic)
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Rodriguez F, et, al. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001 Nov; 75(21): 10421-30. [Content Brief]
[2]. Andargachew R, et, al. CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol. 2018 Jul 1; 201(1):19-30. [Content Brief]
[3]. Homann D, et, al. Mapping and restriction of a dominant viral CD4+ T cell core epitope by both MHC class I and MHC class II. Virology. 2007 Jun 20; 363(1): 113-23. [Content Brief]
[4]. Hilpert C, et al. Dendritic Cells Are Dispensable for T Cell Priming and Control of Acute Lymphocytic Choriomeningitis Virus Infection. J Immunol. 2016 Oct 1;197(7):2780-6. [Content Brief]
[5]. Siracusa F, et al. Nonfollicular reactivation of bone marrow resident memory CD4 T cells in immune clusters of the bone marrow. Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1334-1339. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
LCMV GP (61-80) Related Classifications
HY-P2560 Related Classifications
Powered by Bioz